- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00358774
Efficacy of Homeopathic Nasal Formulation for Management of Experimental Rhinoviral Colds
A Double-blind, Placebo-controlled Trial to Test the Efficacy of Homeopathic Nasal Formulation for the Management of Experimental Rhinoviral Colds in an Outpatient Setting
Common colds affect many people and are the cause of bothersome symptoms such as runny or stuffy nose, sore throat, headache and sneezing. Common colds can also cause more severe illnesses in certain groups of people like the elderly, people with chronic lung diseases such as asthma.
This study is designed to test whether a non-drug (homeopathic) nasal spray will reduce the incidence of colds, decrease cold related symptoms or shorten the length of the cold.
Study Overview
Detailed Description
Common colds are the most frequent type of respiratory infection, and although the clinical manifestations are usually not life threatening or debilitating, they cause annoying symptoms such as nasal congestion, rhinorrhea, malaise, sore throat and sneezing, that can interfere with activities of daily living. Furthermore, colds can cause more severe illnesses in certain people including: infants, the elderly, and people with asthma, chronic lung diseases, or immune deficiency.
This clinical trial is designed to test whether a new homeopathic formulation has beneficial effects on the management of common colds that have been induced by inoculation of rhinovirus into the nose of healthy subjects.
The objective of this research clinical study is to evaluate the effectiveness of a homeopathic nasal formulation for the management of experimentally-induced common colds as indicated by a reduction in:
- Cold incidence compared to placebo,
- Symptom severity compared to placebo
- Cold duration compared to placebo
- Infection rate compared to placebo
- Duration of virus shedding compared to placebo or
- Amount of virus shedding compared to placebo
Study Type
Enrollment
Phase
- Phase 2
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
To be considered eligible for enrollment into this study, subject must:
- Be healthy based on medical history, physical and nasal examination
- Be male or non-pregnant, non-lactating female (women of child-bearing potential must be using an acceptable form of contraception, including abstinence, as determined by the Investigator)
- Be between 18 - 60 years old
- Be willing to refrain from taking nasal decongestants, antihistamines or cough/cold preparations (this includes dietary supplements and homeopathic preparations used specifically for cold/flu e.g., vitamin C, zinc, echinacea) within the 7 days prior to Day 0 and through Day 5
- Be willing to refrain from taking any other medication (except contraceptive preparations, hormone replacement therapy, acne medication) within 2 days prior to Day 0 and through Day 5
- Has read, signed and received a copy of the Informed Consent Form.
Exclusion Criteria:
Subjects will be excluded from the study if they:
- Are intolerant of nasal sprays
- Require a medication on regular basis (3 or more times/week) except contraceptive preparations, hormone replacement therapy, acne medication
- Have a history of chronic diseases such as respiratory (e.g., chronic rhinitis, sinusitis, asthma, chronic bronchitis, pneumonia, persistent or chronic cough, emphysema, breathing problems, excessive phlegm or mucus), cardiovascular, endocrine, neurological, hepatic, gastrointestinal, renal, hematological, urological, immunological, ophthalmic diseases requiring medication
- Have a history of headache (e.g., frequent migraines, cluster headaches, 3+ headaches/week)
- Have had cold symptoms in the past 14 days
- Are currently symptomatic with respiratory allergy
- Have any clinically significant abnormalities of the upper (including history of nose bleeds, nasal abnormalities or other nasal pathology such as irreversible nasal mucosal hypertrophy or severe nasal septal deviation) or lower respiratory tract
- Have used any investigational medication in the past 30 days
- Are smokers
- Have serum neutralizing antibody titer of >1 to RV16 at Pre-screening
- Have a condition or is taking a medication that the Investigator and/or designee believes could jeopardize the safety of the subject, would interfere with the evaluation or confound the interpretation of the study results
- Have positive urine pregnancy test (for female subjects only)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
The proportion of subjects who become infected and show the presence of a cold.(active vs placebo)
|
Secondary Outcome Measures
Outcome Measure |
---|
The proportion of subjects who become infected.
|
The mean number of days that virus was shed for inoculated subjects (active vs placebo)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2001-089
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Common Cold
-
Cardiff UniversityCompletedCommon Cold/FluUnited Kingdom
-
Perrigo CompanyGlaxoSmithKline; Pfizer; McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. and other collaboratorsCompletedNasal Congestion Associated With the Common ColdUnited States
-
NovartisCompletedCommon Cold Associated With CoughCanada
-
Probi ABCompletedAcute Upper Respiratory Tract Infections (Common Cold)Italy
-
Ache Laboratorios Farmaceuticos S.A.Suspended
-
Beijing Da-an Bio-technology Co., Ltd.Unknown
-
Brainfarma Industria Química e Farmacêutica S/ATechtrials Pesquisa e Tecnologia Ltda; PharmagenixUnknown
-
NovartisCompletedSore Throat Due to a Common ColdGermany
-
Boehringer IngelheimCompleted
-
Lund UniversityCoradil ABEnrolling by invitation
Clinical Trials on homeopathic nasal spray
-
VistaGen Therapeutics, Inc.TerminatedSocial Anxiety DisorderUnited States
-
VistaGen Therapeutics, Inc.RecruitingSocial Anxiety DisorderUnited States
-
VistaGen Therapeutics, Inc.CompletedSocial Anxiety DisorderUnited States
-
University of ChicagoMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Withdrawn
-
Viiral Nordic ABCompleted
-
Oyster Point Pharma, Inc.CompletedDry Eye DiseaseUnited States
-
Imperial College LondonGlaxoSmithKlineCompleted
-
Sara EspinozaThe University of Texas Health Science Center, Houston; The University of Texas... and other collaboratorsCompletedObesity | Sedentary Lifestyle | Sarcopenia | Aging | Sarcopenic ObesityUnited States
-
P & B GroupMediAxe CROCompletedAllergic RhinitisFrance
-
P & B GroupMediAxe CROTerminatedSARS-CoV-2 InfectionFrance